PD‐L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR‐mutant non‐small cell lung cancer cells

Bibliographic Details
Main Authors:	Dantong Sun, Puyuan Xing, Junling Li
Format:	Article
Language:	English
Published:	Wiley 2022-12-01
Series:	Cancer Innovation
Subjects:	combination therapy durvalumab osimertinib
Online Access:	https://doi.org/10.1002/cai2.39

Internet

https://doi.org/10.1002/cai2.39